UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
___________
FORM 8-K/A
___________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2009
Commission File Number: 000-26181
AngioGenex, Inc.
(Exact name of small business issuer as specified in its charter)
| | |
Nevada | | 86-0945116 |
(State or other jurisdiction of incorporation or organization) | | (IRS Employer Identification No.) |
|
425 Madison Ave., Suite 902, New York, New York 10017 |
(Address of principal executive offices) |
|
(212) 874-6008 |
(Issuer's telephone number, including area code) |
|
|
(Former name, former address and former fiscal year, If changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| |
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 4. Matters Related to Accountants and Financial Statements
Item 4.01Changes in Registrant's Certifying Accountant.
(1)
This amendment to the Report on Form 8-K that was originally filed with the SEC on May 4, 2009, is a correction to the previous filing because it was filed erroneously due to a miscommunication between AngioGenex and the EDGAR filer service. This original filing was an unfinished draft that was filed prematurely and there has been no change in the Company’s Independent Registered Public Accounting Firm as suggested in the aforementioned 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AngioGenex, Inc. (Registrant)
Date: May 7, 2009
By: /s/ Bill Garland
Bill Garland
President and Chief Executive Officer
